A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
February 14th, 2022
2.8K views
We present a protocol for utilizing a normothermic ex vivo sanguinous perfusion system for the delivery of therapeutics to an entire cardiac allograft in a porcine heterotopic heart transplant model.
Overview
This protocol describes the administration of therapeutics to a whole cardiac allograft in a porcine heterotopic heart transplant model. It allows for extended testing of therapeutic effects on cardiac allografts post-transplantation.
Key Study Components
Area of Science
- Cardiac transplantation
- Therapeutic delivery
- Ex vivo perfusion techniques
Background
- This is the first protocol for administering therapeutics to an entire cardiac allograft.
- The technique is designed for large animal models.
- It addresses challenges in optimizing exposure during transplantation.
- Experienced perfusionists are essential for monitoring the procedure.
Purpose of Study
- To investigate interventions that prevent cardiac allograft rejection.
- To minimize postoperative immunosuppression.
- To extend the lifetime of cardiac allografts.
Methods Used
- Normothermic ex vivo sanguinous perfusion system.
- Large animal model of cardiac transplantation.
- Incision technique for access to the heart.
- Coordination among multiple team members for procedure execution.
Main Results
- Effective administration of therapeutics to cardiac allografts.
- Ability to test therapeutic effects over extended periods.
- Potential to improve outcomes in cardiac transplantation.
Conclusions
- This protocol enhances the understanding of cardiac allograft management.
- It provides a framework for future research on cardiac transplantation.
- Further studies can build on this method to improve transplant success.
Frequently Asked Questions
What is the main advantage of this protocol?
The protocol allows for the testing of therapeutics on whole cardiac allografts over extended periods.
What type of model is used in this study?
A porcine heterotopic heart transplant model is utilized.
Who is needed to coordinate the ex vivo perfusion?
Experienced perfusionists are required to monitor and coordinate the procedure.
What is the purpose of the incision made during the procedure?
The incision provides access to the heart for the transplantation process.
How does this protocol contribute to cardiac transplantation research?
It offers a new method to investigate interventions that can improve transplant outcomes.
Executive Industry Relevance
This protocol enables biopharma R&D teams to evaluate therapeutic interventions on whole cardiac allografts in a clinically relevant large-animal model, supporting mechanistic de-risking of immunomodulatory and gene therapy candidates. By allowing extended post-transplant assessment, it improves predictive confidence in target validation and helps prioritize candidates with sustained allograft protection potential. The model addresses a critical gap in preclinical cardiac transplantation research where systemic delivery and long-term graft function assessment are limited.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses on whole organ immunopathology and graft function over time.
- Operational Value: Provides a reproducible system for functional target validation in immunology and cardiovascular pathways.
- Predictive Value: Supports portfolio triage by identifying therapeutics with durable effects on allograft survival and rejection markers.
Screening & Assay Development
- Assay Readiness: Generates standardized, quantifiable outputs including hemodynamic parameters, oxygen saturation, and hematocrit during ex vivo perfusion.
- Reproducibility: Requires coordinated surgical and perfusion expertise, enabling cross-team standardization for consistent graft preparation.
- Screening Utility: Prepares validated allografts for downstream evaluation of therapeutic compounds or vectors under controlled ex vivo conditions.
Translational & Preclinical Research
- Disease Relevance: Models human cardiac allograft immunopathology and rejection mechanisms in a porcine system.
- Translational Continuity: Bridges discovery to preclinical validation by permitting long-term graft survival assessment (up to 35 days).
- Risk-Adjusted Decisions: Informs go/no-go criteria based on graft viability, reducing late-stage failure risk in cardiac therapy development.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum, enabling early target validation through ex vivo therapeutic delivery and extending into preclinical evaluation via heterotopic transplant and longitudinal monitoring.
- Discovery Biology: Supports hypothesis testing of immunomodulatory and gene delivery interventions on whole allograft physiology.
- Screening: Delivers assay-ready grafts with measurable perfusion parameters for compound or vector screening.
- Analytics: Provides quantitative readouts (aortic pressure, coronary flow, mixed venous O2) to compare therapeutic conditions.
- Translational Research: Connects ex vivo treatment effects to in vivo graft function and survival, enabling biomarker-aligned advancement.
- Enterprise Reuse: Establishes a reusable platform for iterative testing of multiple therapeutic modalities in a single model system.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in immunomodulation and graft protection strategies.
- Operational Value: Standardizes surgical perfusion workflows through defined cannulation, anastomosis, and perfusion monitoring steps.
- Strategic Value: Improves capital efficiency by enabling early identification of therapeutics with durable allograft effects.
- Portfolio Impact: Facilitates risk-adjusted prioritization based on 35-day graft viability and rejection pathology.
Implementation Considerations
- Requires expertise in vascular surgery, perfusion technology, and postoperative large-animal care.
- Dependent on ex vivo perfusion systems capable of normothermic sanguinous support and pressure/flow monitoring.
- Necessitates standardized protocols for anastomosis and graft positioning to prevent kinking or tension.
- Involves adaptation considerations for different therapeutic modalities (viral vectors, small molecules, biologics).
- Limited by the need for specialized facilities and trained personnel for long-term porcine survival studies.
Biopharma FAQs
Why is ex vivo perfusion critical for therapeutic delivery in this model?
Ex vivo perfusion enables direct, whole-organ exposure to therapeutics prior to transplantation, ensuring uniform distribution across the cardiac allograft. This approach avoids first-pass clearance and systemic toxicity, allowing precise dosing and timing of interventions. It supports mechanistic evaluation of drug effects on graft function and immunopathology under controlled conditions.
How does hemodynamic monitoring during perfusion support target validation?
Measurement of aortic pressure, coronary flow, and pulmonary artery output provides real-time assessment of graft function and vascular integrity during therapeutic exposure. These quantitative metrics enable objective comparison of treatment effects on myocardial performance. Stable hemodynamics indicate preserved allograft viability, supporting confident interpretation of therapeutic efficacy.
What quantitative measurements enable assessment of allograft viability post-transplant?
Post-transplant viability is determined by long-term graft survival, with successful models demonstrating function up to 35 days in the heterotopic position. Mixed venous oxygen saturation and hematocrit levels during perfusion serve as early indicators of oxygen-carrying capacity and graft metabolic function. Sustained hemodynamic stability correlates with reduced ischemia-reperfusion injury and improved transplant outcomes.
Why are replication requirements essential for cross-functional collaboration in this protocol?
Reproducibility depends on standardized surgical steps, cannulation techniques, and perfusion parameters executed by coordinated teams of surgeons and perfusionists. Consistent graft preparation ensures that therapeutic effects are not confounded by procedural variability. This reliability enables multi-site or cross-disciplinary studies in immunology, gene therapy, and transplant biology.
What statistical analysis capabilities are required before implementing this model in therapeutic screening?
Implementation requires the ability to compare longitudinal hemodynamic, metabolic, and histopathological data across treatment and control groups. Analysis must account for variability in graft preparation, perfusion duration, and postoperative monitoring. Predefined endpoints such as 35-day survival, rejection scoring, and functional recovery support robust statistical evaluation of therapeutic impact.
Chapters in this video
0:04
Introduction
1:00
Median Sternotomy of the Donor Pig
1:56
Cardiac Arrest and Cardiectomy of the Donor Pig
3:39
Back-Table Preparation of the Donor Heart and Reanimating the Heart
4:47
Preparation of the Recipient and Laparotomy with Vascular Exposure
5:45
Heterotopic Implantation of the Cardiac Graft and Closure of the Laparotomy
6:49
Results: Analysis of Perfusion Parameters and Transplanted Heart
7:36
Conclusion
